EMED Technologies

EMED Technologies

Subcutaneous infusion systems for home care

Overview

EMED Technologies manufactures medical devices and drug delivery systems specifically for subcutaneous infusion of biologics and specialty drugs. Its products, such as the SCIg60 system and VersaPump, use mechanical syringe pumps and variable flow rate controllers to allow patients to safely administer medication at home. Unlike many competitors, the company provides a complete end-to-end B2B solution that includes device design, AI-monitored manufacturing, and final packaging for pharmaceutical partners. The company's goal is to increase patient independence and quality of care by providing accessible, home-based infusion platforms across global markets.

About EMED Technologies

Simplify's Rating
Why EMED Technologies is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Industrial & Manufacturing

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$8M

Headquarters

California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • SCIg market grows at 12.5% CAGR through 2030 from home treatment demand.
  • EMA approved three new biologics for subcutaneous home delivery in 2026.
  • Nipro's Q1 2026 automated line boosts scalability post-2018 technology transfer.

What critics are saying

  • Nipro vertically integrates, cutting EMED needle contracts 50-70% in 12-24 months.
  • 3M divests to Medtronic in 2026, terminating VersaPump deals in 6-12 months.
  • FDA recalls SCIg60 for flow failures, halting sales in 3-9 months.

What makes EMED Technologies unique

  • EMED specializes in patient-centric subcutaneous infusion systems like SCIg60 for home use.
  • VersaPump offers reusable mechanical syringe pump for biologics delivery.
  • Proprietary needle sets SAF-Q and OPTFlow feature recessed safety mechanisms.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8M

Above

Industry Average

Funded Over

1 Rounds

Growth Equity Non VC funding comparison data is currently unavailable. We're working to provide this information soon!
Growth Equity Non VC Funding Comparison
Coming Soon

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Feb 24th, 2026
EMED Subsidiary Closes $8 Million Equity Financing

/PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices announced that its subsidiary closed a...

PR Newswire
Sep 30th, 2025
eMed Population Health Appoints Dr. Dyan Hes as Chief Medical Officer

MIAMI, Sept. 30, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Dr. Dyan Hes as Chief Medical Officer.

Morningstar
Sep 8th, 2025
eMed Population Health Appoints Renowned Industry Leader Amy Elkins as Chief Operating Officer

MIAMI, Sept. 8, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Amy Elkins as Chief Operating Officer.

Investing.com
Aug 18th, 2025
Aon invests in eMed to expand GLP-1 weight management programs By Investing.com

Aon invests in eMed to expand GLP-1 weight management programs

PR Newswire
May 5th, 2025
Emed Announces Collaboration With Aon To Provide A Digital Glp-1 Benefit Program For Aon Colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity managementMIAMI, May 5, 2025 /PRNewswire/ -- eMed®, the leading Population Health technology platform in remote chronic care management and 24/7/365 live care, today announced an industry-changing collaboration with leading global professional services firm, Aon , to provide GLP-1 obesity management services for the company's U.S. employees.This collaboration builds off the momentum from Aon's recently released findings showing a seven percentage point reduction in the growth of medical spend in the second year of GLP-1 therapy, and a 44 percent reduction in risk of hospitalizations caused by major adverse cardiovascular events with adherent GLP-1 utilization. Both eMed and Aon are committed to improving population health by accessible, personalized, and effective healthcare solutions that support better health outcomes and address critical issues such as obesity, diabetes, and related comorbidities."We are thrilled to collaborate with Aon to bring our cutting-edge platform to their employees," said Dr. Patrice Harris, CEO of eMed. "Our platform is a science-based, all-in-one solution proven to deliver superior health outcomes for participants, while enabling employers to manage their spend on GLP-1s. Together with Aon, we're not just offering access to GLP-1s; we're ensuring they are used effectively to improve long-term employee health outcomes as demonstrated by Aon's groundbreaking analysis.""Our findings show that GLP-1s, when combined with holistic support like nutrition, exercise and mental health resources, can deliver lasting health improvements

Recently Posted Jobs

Sign up to get curated job recommendations

EMED Technologies is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →